Key result
Three months of pravastatin (40 mg/day) in adults with mild hypercholesterolaemia lowered mean total cholesterol from 6.6 to 5.5 mmol/L and improved platelet response to nitric oxide.
Why the study?
Does pravastatin improve platelet nitric oxide responsiveness and arterial stiffness in asymptomatic adults with mild hypercholesterolaemia?
Does pravastatin improve platelet nitric oxide responsiveness and arterial stiffness in asymptomatic adults with mild hypercholesterolaemia?
Moderate cholesterol reduction with pravastatin improves platelet responses to nitric oxide, though improvements in arterial stiffness may require more extensive or prolonged lipid lowering.
No takes yet. Share an insight, caveat, or question.
May enhance platelet nitric oxide responsiveness; hypothesis-generating and should not yet change practice.
Stepien et al. (2003) studied Mild hypercholesterolaemia (n=29). Pravastatin vs. Baseline / Normocholesterolaemic subjects was evaluated on Inhibition of platelet aggregation in response to sodium nitroprusside (SNP) and augmentation index (AIx). Three months of pravastatin (40 mg/day) in adults with mild hypercholesterolaemia lowered mean total cholesterol from 6.6 to 5.5 mmol/L and improved platelet response to nitric oxide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: